Literature DB >> 7913875

Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase.

B H Long1, C R Fairchild.   

Abstract

Very low concentrations of paclitaxel, a clinically active anticancer agent isolated from the bark of the Pacific yew tree, were found to produce micronuclei in human colon carcinoma cells, suggesting inhibition of mitotic spindle assembly or function. The possibility that paclitaxel acts at the level of the mitotic spindle was investigated by evaluating its ability to inhibit the progression of mitotic cells to G1 phase. Paclitaxel inhibited mitotic progression with a median inhibitory concentration of 4 nM, a concentration equivalent to the median cytotoxic concentration, without arresting cells in mitosis. A direct correlation was shown to exist between the cytotoxic potency and ability to inhibit mitotic progression for analogues of paclitaxel and antimicrotubule agents but not for the topoisomerase II-active agents etoposide and teniposide. After release from the nocodazole block, cells synchronized in mitosis remained sensitive to very low concentrations of paclitaxel for < 30 min, the time required for spindle formation, yet remained sensitive to vinblastine for > 90 min. This result indicates that very low concentrations of paclitaxel inhibit formation of mitotic spindles in cells without affecting function of preformed spindles and without arresting cells in mitosis. Continuous exposure to low nanomolar concentrations of paclitaxel for more than one cell cycle resulted in cells with DNA contents > 4C and as much as 8C. These results support a hypothesis, that, by not being capable of segregating sister chromatids, paclitaxel-treated cells eventually reform nuclear membranes around individual or clusters of chromosomes, revert to G1 phase cells containing 4C DNA, and enter S phase, resulting in cells with as much as 8C DNA content. It is proposed that this is the primary cytotoxic mechanism of paclitaxel.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913875

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Establishment of a tetraploid Meth-A cell line through polyploidization by demecolcine but not by staurosporine, K-252A and paclitaxel.

Authors:  K Fujikawa-Yamamoto; S Wang; H Yamagishi; C Ohdoi; H Murano; T Ikeda
Journal:  Cell Prolif       Date:  2001-08       Impact factor: 6.831

Review 2.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

Review 3.  Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.

Authors:  G Pentheroudakis; E Razis; A Athanassiadis; N Pavlidis; G Fountzilas
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Microtubule Dynamicity Is More Important than Stability in Memory Formation: an In Vivo Study.

Authors:  Deyhim Atarod; Ghazaleh Eskandari-Sedighi; Farid Pazhoohi; Seyed Morteza Karimian; Mojtaba Khajeloo; Gholam Hossein Riazi
Journal:  J Mol Neurosci       Date:  2015-03-05       Impact factor: 3.444

5.  Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors.

Authors:  N J Millenbaugh; Y Gan; J L Au
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

6.  OVEREXPRESSION OF BOTH CLOCK AND BMAL1 INHIBITS ENTRY TO S PHASE IN HUMAN COLON CANCER CELLS.

Authors:  Wataru Sakamoto; Seiichi Takenoshita
Journal:  Fukushima J Med Sci       Date:  2015-09-11

7.  In vivo optical pathology of paclitaxel efficacy on the peritoneal metastatic xenograft model of gastric cancer using two-photon laser scanning microscopy.

Authors:  Tadanobu Shimura; Koji Tanaka; Yuji Toiyama; Masato Okigami; Shozo Ide; Takahito Kitajima; Satoru Kondo; Susumu Saigusa; Masaki Ohi; Toshimitsu Araki; Yasuhiro Inoue; Keiichi Uchida; Yasuhiko Mohri; Akira Mizoguchi; Masato Kusunoki
Journal:  Gastric Cancer       Date:  2014-01-08       Impact factor: 7.370

Review 8.  Crucial functionalizations of carbon nanotubes for improved drug delivery: a valuable option?

Authors:  Giorgia Pastorin
Journal:  Pharm Res       Date:  2009-01-14       Impact factor: 4.200

9.  Mitotic slippage in non-cancer cells induced by a microtubule disruptor, disorazole C1.

Authors:  Fengfeng L Xu; Youssef Rbaibi; Kirill Kiselyov; John S Lazo; Peter Wipf; William S Saunders
Journal:  BMC Chem Biol       Date:  2010-02-11

10.  Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival.

Authors:  Praful R Nair; Cory Alvey; Xiaoling Jin; Jerome Irianto; Irena Ivanovska; Dennis E Discher
Journal:  Bioconjug Chem       Date:  2018-03-01       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.